$ONC

Wu Xiaobin sold $357K of ONC

Wu Xiaobin (President and COO) sold 1,292 shares of BeOne Medicines Ltd. (ONC) at $276.26 ($0.36M total) on 2026-06-23.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 25, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

This provides a fresh, primary-source datapoint on insider behavior (sale size, price, and post-sale holdings), but it does not include any new operational or clinical/regulatory catalyst.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a sustained repricing without additional company-specific news.

03

What to watch

Insider sales often reflect diversification, tax planning, or scheduled liquidity needs; the filing shows holdings after transaction are 0 shares, but provides no stated rationale.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-25 after-hours; reflects sale executed 2026-06-23.

Background

The article is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

SEC Form 4 shows Wu Xiaobin (President & COO) sold 1,292 ONC shares for about $356,927 on 2026-06-23.

Expected impact

Low near-term impact; any reaction is likely muted unless follow-on sales or other disclosures emerge.

Evidence & confidence

The filing is a Form 4 insider transaction with a small absolute size and no 10b5-1 plan stated; however, insider sales are common and not inherently bearish without additional context.

Market effects

Minimal—single-company insider sale in a biotech/meds name does not materially change sector risk.

Minimal—no macro or cross-regional linkage in the filing details.

Minimal—no deal, trial, or regulatory action affecting global markets is disclosed.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as near-term caution.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction; President & COO Wu Xiaobin sold shares.

  • Wu Xiaobin

    President and COO who executed an open-market sale of 1,292 shares.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.